Chanelle Pharma Names New CEO, Embracing “One-Health” Strategy
Chanelle Pharma, the leading manufacturer of generic medications for both humans and animals in Ireland, has appointed Angelo Gatto as its new Chief Executive Officer (CEO). Gatto brings over 25 years of extensive international experience in the pharmaceuticals sector, spanning animal health, human health, and contract development and manufacturing organizations (CDMO).
This strategic appointment follows the acquisition of Chanelle Pharma by Exponent, a prominent British private equity group, earlier this year. Gatto played a pivotal role on Exponent’s advisory team during the investment process, providing valuable insights and expertise.
Leading Chanelle Pharma into a New Chapter
Gatto’s impressive career includes significant roles in key areas of the pharmaceutical industry. He held operational, commercial, and management positions at renowned companies such as Johnson & Johnson, Pfizer, Aenova Group, and Adragos Pharma. His vast experience across various sectors, coupled with his deep understanding of the pharmaceutical landscape, positions him well to lead Chanelle Pharma through its next phase of growth and innovation.
“One-Health” Focus: A Key Differentiator
Gatto’s appointment is a testament to Chanelle Pharma’s commitment to its “one-health” strategy. This innovative approach emphasizes the interconnectedness of human and animal health, aiming to create a holistic and sustainable healthcare system. Gatto recognizes the strength of Chanelle Pharma’s brand and its unique positioning in the “one-health” market.
“Chanelle Pharma has built an incredible brand with strong foundations and a unique positioning for ‘one-health’, which focuses on both human and animal health,” Mr. Gatto stated. “I look forward to working closely with our team, leveraging strong capabilities to foster our emerging product pipeline.”
A Legacy of Excellence: Michael Burke’s Impact
Chanelle Pharma was founded by Michael Burke, who spearheaded the company for over 40 years, establishing it as a dominant force in the generic pharmaceuticals market. Burke’s visionary leadership and commitment to quality led to the company’s remarkable success and growth. The acquisition by Exponent marked a significant turning point for Chanelle Pharma, ushering in a new era of expansion and innovation.
However, with the sale to Exponent, Burke retired from the business. The day-to-day operations were overseen by a seasoned executive team, including Aubrey Mulveen, the Chief Financial Officer; Kara Walsh, the Chief People Officer; Aiden Dempsey, the Chief Information Officer; and Brian O’Broin, the Chief Quality and Technology Officer. This team played a crucial role in maintaining the company’s smooth operations and strategic direction during the transition period.
A New Leader at the Helm: Confidence in Gatto’s Expertise
Chanelle Pharma’s chairman, Carsten Hellmann, expressed his confidence in Gatto’s ability to lead the company through this exciting new chapter.
“Angelo brings relevant experience in all our business areas, and has demonstrated remarkable excellence throughout his entire career,” said Chanelle chairman Carsten Hellmann. “I am confident in his ability to lead Chanelle Pharma through this exciting next chapter.”
Gatto’s Vision: Shaping the Future of Chanelle Pharma
Gatto’s appointment marks a new era for Chanelle Pharma. He is poised to leverage his vast experience and proven leadership skills to drive the company’s strategic growth initiatives. His focus on “one-health” and his dedication to fostering innovation and emerging product pipelines will shape Chanelle Pharma’s future as a leader in the global pharmaceuticals market.
A Global Reach: Expanding Chanelle Pharma's Footprint
Chanelle Pharma’s commitment to global expansion is evident in its operations across Ireland, the UK, Portugal, and Jordan. The company employs over 700 individuals, reflecting its dedication to fostering a diverse and talented workforce. Gatto’s leadership is expected to further drive this global expansion, strengthening Chanelle Pharma’s presence in key markets and solidifying its position as a leading global player in the pharmaceutical industry.
The Future is Bright: A New Era of Growth and Innovation
Chanelle Pharma’s future looks promising under Gatto’s leadership. His commitment to innovation, strategic partnerships, and a focus on “one-health” positions the company for continued growth and success. The pharmaceutical industry is a dynamic and rapidly evolving landscape, and Gatto’s experience, coupled with his passion for the “one-health” approach, makes him the ideal leader to navigate this complex and challenging environment. Chanelle Pharma is well-positioned to capitalize on the opportunities presented by the global pharmaceuticals market, and Gatto’s appointment is a clear signal of the company’s commitment to growth and innovation.
